Voyager Therapeutics Inc (NASDAQ:VYGR) CFO Jane Henderson sold 17,316 shares of the business’s stock in a transaction on Monday, March 19th. The stock was sold at an average price of $22.11, for a total transaction of $382,856.76. Following the completion of the transaction, the chief financial officer now directly owns 15,416 shares in the company, valued at approximately $340,847.76. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link.
Jane Henderson also recently made the following trade(s):
- On Friday, March 16th, Jane Henderson sold 15,416 shares of Voyager Therapeutics stock. The shares were sold at an average price of $22.15, for a total transaction of $341,464.40.
Shares of Voyager Therapeutics Inc (VYGR) opened at $20.50 on Friday. Voyager Therapeutics Inc has a 12 month low of $8.10 and a 12 month high of $31.91. The firm has a market cap of $681.98, a price-to-earnings ratio of -7.68 and a beta of 2.37.
Voyager Therapeutics (NASDAQ:VYGR) last announced its earnings results on Wednesday, March 14th. The company reported ($0.40) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.72) by $0.32. Voyager Therapeutics had a negative net margin of 697.03% and a negative return on equity of 63.18%. The business had revenue of $6.35 million for the quarter, compared to the consensus estimate of $5.81 million. analysts anticipate that Voyager Therapeutics Inc will post -2.54 earnings per share for the current fiscal year.
Institutional investors and hedge funds have recently made changes to their positions in the company. Wells Fargo & Company MN raised its stake in shares of Voyager Therapeutics by 312.8% in the third quarter. Wells Fargo & Company MN now owns 377,190 shares of the company’s stock valued at $7,766,000 after acquiring an additional 285,806 shares during the period. Aevitas Wealth Management Inc. purchased a new stake in shares of Voyager Therapeutics in the fourth quarter valued at $1,400,000. Vanguard Group Inc. raised its stake in shares of Voyager Therapeutics by 3.2% in the second quarter. Vanguard Group Inc. now owns 430,765 shares of the company’s stock valued at $3,860,000 after acquiring an additional 13,194 shares during the period. Bank of New York Mellon Corp raised its stake in shares of Voyager Therapeutics by 16.2% in the third quarter. Bank of New York Mellon Corp now owns 61,858 shares of the company’s stock valued at $1,274,000 after acquiring an additional 8,633 shares during the period. Finally, Victory Capital Management Inc. purchased a new stake in shares of Voyager Therapeutics in the fourth quarter valued at $1,210,000. 80.03% of the stock is currently owned by institutional investors and hedge funds.
A number of research firms recently issued reports on VYGR. Zacks Investment Research downgraded shares of Voyager Therapeutics from a “buy” rating to a “hold” rating in a research note on Tuesday. BidaskClub downgraded shares of Voyager Therapeutics from a “buy” rating to a “hold” rating in a research note on Friday, March 9th. Piper Jaffray Companies reaffirmed a “buy” rating and set a $40.00 price target on shares of Voyager Therapeutics in a research note on Monday, March 12th. BTIG Research reaffirmed a “buy” rating and set a $32.00 price target on shares of Voyager Therapeutics in a research note on Sunday, March 11th. Finally, Canaccord Genuity set a $35.00 price target on shares of Voyager Therapeutics and gave the company a “buy” rating in a research note on Wednesday, March 14th. Two analysts have rated the stock with a sell rating, three have given a hold rating and nine have issued a buy rating to the company. The company presently has a consensus rating of “Buy” and an average target price of $29.73.
TRADEMARK VIOLATION WARNING: “Voyager Therapeutics Inc (VYGR) CFO Sells $382,856.76 in Stock” was originally posted by The Lincolnian Online and is owned by of The Lincolnian Online. If you are viewing this story on another publication, it was stolen and republished in violation of U.S. & international trademark and copyright law. The correct version of this story can be viewed at https://www.thelincolnianonline.com/2018/03/23/voyager-therapeutics-inc-vygr-cfo-sells-382856-76-in-stock.html.
Voyager Therapeutics Company Profile
Voyager Therapeutics, Inc is a clinical-stage gene therapy company. The Company focuses on developing treatments for patients suffering from severe diseases of the central nervous system (CNS). The Company’s pipeline consists of programs for CNS indications, including advanced Parkinson’s disease; a monogenic form of amyotrophic lateral sclerosis (ALS); Huntington’s disease; Friedreich’s ataxia; frontotemporal dementia/Alzheimer’s disease, and severe chronic pain.
Receive News & Ratings for Voyager Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Voyager Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.